Pathos AI committed up to $2.2 billion to license cancer drugs from Alphamab and AstraZeneca without inventing a single molecule. Inside the bet that AI's real job is picking patients, not chemistry.
Lilly and its manufacturing partner Resilience are putting $750 million into an Ohio campus to make more of the injector pens behind the diabetes and obesity boom -- 400 new jobs, full operations by early 2027.
Celcuity's first FDA drug, REVTORPYK, cut breast-cancer progression risk 76% and stretched median control from 2.0 to 9.3 months — yet the stock slid on a delayed launch and rough side effects.
Lilly's triple-G shot retatrutide hit 30.3% weight loss in Phase 3 — surgery territory. Then the FDA filing slipped to Q1 2027 over manufacturing.
Eli Lilly's triple-agonist shot retatrutide hit 22.6% weight loss in two more Phase 3 trials — its fifth straight win, with an FDA filing due Q1 2027.
Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a once-daily pill that cuts LDL up to 59%, matching the injectables at $315 a month.
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.
Feature Image: https://images.unsplash.com/photo-1648792940059-3b782a7b8b20?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w3ODQzODd8MHwxfHNlYXJj...
BREAKING NEWS — In a move that signals the pharmaceutical industry's full-scale embrace of artificial intelligence, Swiss healthcare giant Roche has ...
Scientists can now print mini-tissues, partial organs, and vascular networks. But printing a fully functional, transplant-ready human organ? Still at least 20–30 years away.
